Dr David Spigel speaks to ecancer about the on-going MERMAID-2 phase 3 study of durvalumab in patients with resected, stage II-III NSCLC who become MRD positive after curative-intent therapy.
Initially, he explains the rationale behind this study; detection of minimal residual disease (MRD), as indicated by circulating tumour DNA (ctDNA), may indicate the presence of clinically indiscernible residual tumour following curative-intent therapy and enable earlier therapeutic intervention, thereby improving outcomes in patients at highest risk of recurrence.
Dr Spigel then, discusses the trial design and expected end-points of this study.
The primary endpoint is DFS in patients with PD–L1 tumour cell expression ≥1%.
Secondary endpoints include DFS in the full analysis set, progression-free survival, OS, time to subsequent therapy, patient-reported outcomes, and safety.
In the end, Dr Spigel says that the trial is recruiting patients right now but there has been some preliminary research by Dr Swanton that is noteworthy.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.